OT

OnKure Therapeutics, Inc.

OKUR·NASDAQ

$4.47

+8.5%
HealthcareBiotechnology

OnKure, Inc. engages in the discovery and development of oncology-precision medicines for the treatment of cancer. The company focuses on developing selective inhibitors of histone deacetylases. Its portfolio includes OKI-179, an inhibitor for the treatment of both hematological and solid tumors. The company was incorporated in 2011 and is based in Boulder, Colorado.

At a Glance

Live Snapshot
Market Cap$61.12M
EPS-4.4000
P/E Ratio-1.02
Earnings Date08/11/2026

okur

Prepaids

Last Annual Value

0.00

3-Year CAGR

%

5-Year CAGR

%

10-Year CAGR

%

OT

OnKure Therapeutics, Inc. Competitors Analysis of Prepaids

OKUR · NASDAQ
CompanyPrepaids
CAGR 3Y
CAGR 5Y
CAGR 10Y
0.00
N/AN/AN/A 
0.00
N/AN/AN/A
535.00K
-43.9%-26.9%14.2%
0.00
N/AN/AN/A
294.10K
-17.3%-21.7%-11.4%
0.00
N/AN/AN/A
1.25M
-2.9%-3.4%-3.8%
0.00
N/AN/AN/A
OT

OnKure Therapeutics, Inc. Fair Value Envelope

OKUR · NASDAQ

Our analysis suggests that OKUR has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $4.47, this represents a potential HIDDEN relative to our calculated worth for OnKure Therapeutics, Inc..

Intrinsic Value
Current Price: $4.47